A Phase 3, 1-Year, Open-Label Trial of Valbenazine in Adults With Tardive Dyskinesia.

Overview of attention for article published in Journal of Clinical Psychopharmacology, November 2019

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#47 of 3,822)
High Attention Score compared to outputs of the same age (96th percentile)
High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

news: 8 news outlets

twitter: 2 X users

Readers on

mendeley: 52 Mendeley

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 1,586 followers.

Current Issue: A Phase 3, 1-Year, Open-Label Trial of Valbenazine in Adults With Tardive Dyskinesia https://t.co/rPiTZtGj0i

In patients with TD, improvements during long-term treatment (week 48) were observed with valbenazine (AIMS total score = -10.42 with 40 mg/d and -11.0 with 80 mg/d). Also, most participants had response (40 mg/d = 90.0%; 80 mg/d = 89.2%) https://t.co/a…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.